DelveInsight’s ‘Catheter-Related Bloodstream Infection (CRBSI) Market’ report delivers an in-depth understanding of the CRBSI historical and forecasted epidemiology, market trends in the 7MM.
Catheter-Related Bloodstream Infection Overview
Catheter-related bloodstream infection also known as catheter-related sepsis, defined as the presence of bacteremia originating from a catheter insertion. Antibiotics such as antibacterial and antifungal are used for the treatment of the disease. Antibiotic lock therapy is considered as adjunctive therapy in the treatment of CRBSI when catheter removal is not a favorable option. The current treatment options are used as off-label therapies and only a few non-antibiotic lock solutions are approved in Europe.
The diagnosis of catheter-related bloodstream infection remains a major challenge. Fever and chills that are often associated with catheter-related bloodstream infections are not specific. Furthermore, local catheter inflammation and phlebitis could exist in the absence of catheter-related bloodstream infection or even a local infection, as has been reported with peripherally inserted central catheters.
It covers the details of conventional and current medical therapies available in the catheter-related bloodstream infection market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the United States and Spain.
The DelveInsight’s catheter-related bloodstream infection market report gives a thorough understanding of catheter-related bloodstream infection by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.
CRBSI Epidemiology Key Findings
This section provides glimpses of the catheter-related bloodstream infection epidemiology in the market.
As per DelveInsight’s analysis, the total incident population of catheter-related bloodstream infection in the 7MM was found to be approximately 4,115,000 in 2019.
CRBSI Marketed Drugs
1. Neutrolin by CorMedix
2. Taurosept by Geistlich Pharma
CRBSI Off-label Drugs
CRBSI Emerging Drugs
1. Mino-Lok: Citius Pharmaceuticals
CRBSI Market Outlook
The catheter-related bloodstream infection market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted catheter-related bloodstream infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
According to DelveInsight, catheter-related bloodstream infection global market is expected to change in the study period 2019–2032.
Download our full report: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
Table of contents
1 Key Insight
2 Executive Summary of Catheter-Related Bloodstream Infection (CRBSI)
3 Catheter-Related Bloodstream Infection (CRBSI) Market Overview at a Glance
4 Disease Background and Overview: Catheter-Related Bloodstream Infection (CRBSI)
5 Case Reports
6 Catheter-Related Bloodstream Infection (CRBSI) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Catheter-Related Bloodstream Infection (CRBSI) Treatment and Medical Practices
11 Unmet needs
12 Catheter-Related Bloodstream Infection (CRBSI) Marketed Drugs
13 Catheter-Related Bloodstream Infection (CRBSI) Emerging Drugs
14 Catheter-Related Bloodstream Infection (CRBSI) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Catheter-Related Bloodstream Infection (CRBSI) Market Drivers
19 Catheter-Related Bloodstream Infection (CRBSI) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
23 DelveInsight Capabilities
25 About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States